Core Viewpoint - Vaxart, Inc. is set to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, highlighting its focus on developing oral vaccines using a proprietary delivery platform [1][2]. Company Overview - Vaxart is a clinical-stage biotechnology company specializing in oral recombinant vaccines that can be stored and shipped without refrigeration, thus eliminating needle-stick injury risks [3]. - The company is developing vaccines targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV), marking its entry into immune-oncology [3]. - Vaxart has filed extensive domestic and international patent applications for its oral vaccination technology, which utilizes adenovirus and TLR3 agonists [3]. Presentation Details - The presentation is scheduled for February 25, 2026, at 4:00 PM ET, and will be available for 30 days on the company's investor relations website [2]. - Vaxart will also engage in one-on-one meetings during the conference for interested investors [2].

Core Insights - Penny stocks attract speculative investors seeking high-risk/high-reward opportunities, often focusing on companies with disruptive technologies or compelling turnaround stories [3] - MarketBeat provides a tool listing the 100 Most Popular Penny Stocks based on subscriber interest, which may enhance investor confidence despite not guaranteeing success [4] Company Insights - Vaxart Inc. (NASDAQ: VXRT) is a clinical-stage biotechnology company developing oral vaccines for infectious diseases, aiming to simplify distribution and improve global accessibility [5] - The bull case for Vaxart hinges on its innovative oral vaccine platform, which could significantly impact global immunization efforts if FDA approval is obtained and successful scaling occurs [5] - Clinical risk is a major challenge for Vaxart, as it has not yet brought a product to market, and the vaccine development process is costly and unpredictable [6] Industry Insights - The biotechnology sector is characterized by high volatility and significant competition, particularly from established players with larger R&D budgets [6] - Other companies in the speculative investment space include Microvision, which develops lidar technology for autonomous vehicles, and Datavault AI, which focuses on monetizing digital data through AI and blockchain tools [7]

Company Overview - Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary delivery platform [3] - The company aims to create vaccines that can be administered in pill form, which can be stored and shipped without refrigeration, thus eliminating the risk of needle-stick injuries [3] - Vaxart's current development programs include vaccines targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [3] Upcoming Event - Vaxart will participate in the Global BioInnovation Forum, a virtual event featuring senior leaders in life sciences and health innovation [1] - Key speakers at the event will include Steven Lo (CEO), Sean Tucker (Founder and CSO), and James F. Cummings (CMO) [2] - The event is scheduled for January 13, 2026, at 11:30 AM PT, and the webcast will be available for 30 days post-event on the company's investor relations website [2]

Market Overview - U.S. stock markets faced a significant downturn on November 13, 2025, marking one of the worst trading days since April, driven by concerns over high valuations of AI-related stocks and skepticism regarding the Federal Reserve's interest rate cuts [1][10] - Major indexes closed sharply lower, with the Nasdaq Composite dropping 2.3%, the S&P 500 falling 1.7%, and the Dow Jones Industrial Average shedding approximately 797 points, or 1.7% [2][10] Sector Performance - The negative sentiment was largely due to a rotation out of high-flying technology and AI stocks, as investors questioned the sustainability of their rapid gains, leading to a shift towards more defensive market areas [3] - Treasury yields increased, adding pressure to stock valuations, particularly for growth-oriented companies [3] Company-Specific News - Nvidia (NVDA) was a major drag on the market, with shares falling between 3.6% and 4.2%, as investor scrutiny over its valuation increased [5] - Tesla (TSLA) shares declined nearly 7% due to a steep year-over-year sales decline in China, highlighting competition and demand challenges [5] - The Walt Disney Co. (DIS) saw its shares tumble between 7.8% and 8.9% after missing quarterly sales forecasts, despite exceeding profit expectations [5] - Alphabet (GOOGL) experienced a notable drop of 2.3% amid the broader tech sell-off [5] - Cisco Systems (CSCO) rose 4.5% after boosting its full-year profit and revenue forecasts, driven by strong demand for networking equipment [5] - Sealed Air (SEE) shares soared between 16% and 19.6% following reports of a potential take-private deal [5] - Verizon Communications (VZ) shares rose 0.7% on plans to cut approximately 15,000 jobs for cost optimization [5] - Other AI-related stocks faced declines, including Super Micro Computer (SMCI) down 7.4%, Palantir Technologies (PLTR) down between 6.5% and 6.7%, and Broadcom (AVGO) down between 4.3% and 5.65% [5] - Companies in the cryptocurrency space also saw declines, with Robinhood Markets (HOOD) dropping nearly 9%, Interactive Brokers (IBKR) losing 7.8%, and Coinbase Global (COIN) sinking 6.9% [5] Economic Data and Federal Reserve Outlook - The market is awaiting crucial economic data, including the Consumer Price Index (CPI) and employment reports for October, which are expected to be delayed due to the recent end of the federal government shutdown [4][6] - The Federal Reserve's stance on interest rates remains a dominant theme, with skepticism about another rate cut in December, as the probability of a 25-basis-point cut decreased from 70% to approximately 53% [7] Upcoming Events - Nvidia's upcoming earnings report is highly anticipated, as it could serve as a significant test for the prevailing optimism surrounding AI technology [8]

Core Insights - Vaxart has entered into an exclusive license agreement with Dynavax for its COVID-19 oral pill vaccine candidate, potentially generating up to $700 million in cumulative proceeds plus royalties [1][4][3] - The company has completed enrollment of approximately 5,400 participants in its COVID-19 Phase 2b trial, with topline data expected in late 2026 and data from a 400-person sentinel cohort anticipated in the first quarter of 2026 [1][9] - Vaxart reported positive data from its Phase 1 clinical trial for its second-generation oral norovirus vaccine, indicating improved protection against infection [1][3] COVID-19 Vaccine Developments - The exclusive agreement with Dynavax includes a $25 million upfront license fee and a $5 million equity investment, with additional potential payments of $50 million and up to $195 million in regulatory milestone payments [4] - Vaxart retains operational and financial responsibility for the oral COVID-19 vaccine program through the completion of the ongoing Phase 2b clinical trial [4] - The company has received $125.9 million in cash payments associated with its COVID-19 vaccine program as of September 30, 2025 [9] Norovirus Vaccine Developments - Vaxart's second-generation oral pill norovirus vaccine constructs have shown significantly stronger antibody responses compared to first-generation constructs [3][9] - The company plans to publish complete results of the Phase 1 study in a peer-reviewed journal and is exploring partnership opportunities for its norovirus candidate [3][9] Financial Results for Q3 2025 - Vaxart reported revenue of $72.4 million for Q3 2025, a significant increase from $4.9 million in Q3 2024, primarily from government contracts [9][15] - Research and development expenses rose to $75.9 million in Q3 2025 from $15.1 million in Q3 2024, mainly due to increased clinical trial expenses [9][15] - The net loss for Q3 2025 was $8.1 million, an improvement from a net loss of $14.1 million in Q3 2024, with a net loss per share of $0.04 compared to $0.06 [9][15] Cash Position and Runway - As of September 30, 2025, Vaxart had cash, cash equivalents, and investments totaling $28.8 million, with a current runway extended into the second quarter of 2027 following the Dynavax agreement [1][9]

Core Points - Vaxart, Inc. will host a conference call to discuss its third quarter 2025 financial results on November 13, 2025, at 4:30 p.m. ET [2] - A stockholder fireside chat is scheduled for November 18, 2025, at 4:30 p.m. ET, where senior management will address frequently asked questions from stockholders [3] Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform that allows for non-refrigerated storage and eliminates needle-stick injury risks [5] - The company's vaccine development programs include oral vaccines targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [5] - Vaxart has filed extensive domestic and international patent applications for its oral vaccination technology, which utilizes adenovirus and TLR3 agonists [5]

Core Insights - Crinetics Pharmaceuticals, Inc. (CRNX) reported a quarterly loss of $1.38 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.27, and compared to a loss of $0.96 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $0.14 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 94.7%, while revenues were zero a year ago [2] - The stock has underperformed, losing about 16.8% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] Financial Performance - The earnings surprise for the recent quarter was -8.66%, and the company has only surpassed consensus EPS estimates once in the last four quarters [2][3] - The current consensus EPS estimate for the upcoming quarter is -$1.30 on revenues of $3.25 million, and for the current fiscal year, it is -$4.85 on revenues of $4.98 million [7] Market Outlook - The company's stock is currently rated Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] - The outlook for the Medical - Drugs industry, where Crinetics operates, is relatively strong, ranking in the top 39% of over 250 Zacks industries, suggesting potential for better performance compared to lower-ranked industries [8]

Core Insights - Dynavax Technologies Corporation reported significant progress in its strategic initiatives during Q3 2025, particularly in the commercial performance of HEPLISAV-B and advancements in its vaccine pipeline [2][5][6]. Business Updates - Dynavax entered into an exclusive license agreement with Vaxart for its oral COVID-19 vaccine candidate, which is currently in Phase 2b clinical trials [3][6]. - The company authorized a new share repurchase program of up to $100 million, reflecting confidence in its future and commitment to returning value to shareholders [4][7]. Financial Highlights - HEPLISAV-B achieved quarterly net product revenue of $90 million, marking a 13% year-over-year increase from $79.3 million in Q3 2024 [5][16]. - Total revenues for Q3 2025 were $94.9 million, an 18% increase compared to $80.6 million in Q3 2024 [16]. - GAAP net income for Q3 2025 was $26.9 million, or $0.23 per share, compared to $17.6 million, or $0.13 per share, in Q3 2024 [16][31]. Market Position - HEPLISAV-B's total estimated market share in the U.S. increased to approximately 46%, up from 44% in Q3 2024, with retail market share growing to about 63% from 55% [10][16]. - The U.S. hepatitis B adult vaccine market is expected to peak at over $900 million in annual sales by 2030, with HEPLISAV-B projected to achieve at least 60% market share [10][16]. Clinical Pipeline - Dynavax is advancing its shingles vaccine candidate Z-1018, which has shown positive topline data in clinical trials, and is expected to report further results in 2026 [11][12]. - The company is also developing a plague vaccine candidate and a Lyme disease vaccine candidate, both leveraging its CpG 1018 adjuvant technology [9][12][16].

Core Insights - Dynavax Technologies Corporation and Vaxart, Inc. have entered into an exclusive worldwide license and collaboration agreement for Vaxart's investigational oral COVID-19 vaccine candidate [1][3][6] Financial Terms - Dynavax will pay Vaxart an upfront license fee of $25 million and make a $5 million equity investment [3][10] - Additional payments may include up to $50 million after Phase 2b results, $195 million in regulatory milestone payments, and $425 million in potential future net sales milestone payments [10] Vaccine Development - Vaxart's oral vaccine candidate utilizes a novel mechanism of action and delivery method, aiming to induce mucosal immunity and improve patient acceptance [2][4] - The ongoing Phase 2b clinical trial involves approximately 5,400 participants and compares Vaxart's oral vaccine to an FDA-approved mRNA vaccine [7][10] Collaboration Goals - The collaboration aims to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine options [6][10] - Vaxart will retain operational and financial responsibility for the oral COVID-19 vaccine program through the completion of the Phase 2b trial [3][10] Strategic Importance - The agreement allows Dynavax to evaluate Phase 2b data before committing to late-stage development, aligning with its strategy to build a diversified vaccine portfolio [4][6] - Vaxart's proprietary VAAST™ platform is designed for room-temperature stable pill vaccines, potentially enhancing global distribution and compliance [4][8]

Core Insights - Vaxart, Inc. is presenting research on its second-generation norovirus oral pill vaccine candidate at IDWeek 2025, highlighting advancements in its vaccine development efforts [1][2] Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform [2] - The company's vaccines are designed to be administered in pill form, which can be stored and shipped without refrigeration, thus eliminating the risk of needle-stick injuries [2] - Vaxart's current development programs include vaccines targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [2] - The company has filed broad domestic and international patent applications for its proprietary technology related to oral vaccination using adenovirus and TLR3 agonists [2] Presentation Details - The presentation at IDWeek 2025 will feature an open-label Phase 1 clinical trial demonstrating improved immune responses to norovirus strains GI.1 and GII.4 from a next-generation oral bivalent vaccine candidate [2] - The session is scheduled for October 20, 2025, from 1:45 PM to 3:00 PM ET at the Georgia World Congress Center in Atlanta [2]